In A Small Feasibility Study, Ugn-102 Achieves A Complete Response In 75% (6 Of 8) Patients
15/02/2023 14:17
Urogen Pharma Ltd UR8.F :
* UROGEN PHARMA LTD - IN A SMALL FEASIBILITY STUDY, UGN-102
ACHIEVES A COMPLETE RESPONSE IN 75% (6 OF 8) PATIENTS
Source text for Eikon: ID:nBwbG02NFa
Further company coverage: UR8.F
Recent news on UroGen Pharma
See all newsBrief: Urogen Submits NDA For Ugn-103, An Investigational Treatment Of Recurrent Lg-Ir-Nmibc
Reports 36-Month Duration Of Response Of 64.5% For ZUSDURI In Phase 3 Envision Trial
Brief: Journal Of Urology Publishes Envision Trial Results Showing 72.2% 24-Month Duration Of Response With Zusduri
Brief: Urogen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Urogen Announces Refinanced Term Loan Agreement With Pharmakon Advisors